An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer
INTRODUCTION: Treatment of unresectable or metastatic urothelial carcinoma (UC) has historically relied upon platinum-based chemotherapy and, more recently, immune checkpoint inhibitors. When tumors progress despite those therapies, remaining effective options are limited.
AREAS COVERED: In this review, the authors review the advancement in genomic targets in UC, most notably fibroblast growth factor receptor (FGFR). FGFR has been identified as a target in UC as it is commonly genomically altered (activating mutations or fusions), and may be enriched in UC subtypes that are relatively resistant to immune checkpoint blockade. Erdafitinib, a potent and selective inhibitor of FGFRs, represents the first targeted therapy approved for the treatment of UC by virtue of a confirmed response rate of 40% in an open-label, single-armed phase II trial in molecularly selected tumors. The authors provide their expert opinion of its approval and place it in the context of the current and forthcoming treatment strategies for metastatic UC.
EXPERT OPINION: The approval of erdafitinib provides clinicians with an important new treatment option for patients with metastatic UC and projects forward into an era of enhanced molecular precision in identifying effective therapies in UC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 21(2020), 8 vom: 16. Juni, Seite 863-870 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nauseef, Jones T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.07.2020 Date Revised 14.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14656566.2020.1736036 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307161153 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307161153 | ||
| 003 | DE-627 | ||
| 005 | 20231225124942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2020.1736036 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM307161153 | ||
| 035 | |a (NLM)32124650 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nauseef, Jones T |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2020 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Treatment of unresectable or metastatic urothelial carcinoma (UC) has historically relied upon platinum-based chemotherapy and, more recently, immune checkpoint inhibitors. When tumors progress despite those therapies, remaining effective options are limited | ||
| 520 | |a AREAS COVERED: In this review, the authors review the advancement in genomic targets in UC, most notably fibroblast growth factor receptor (FGFR). FGFR has been identified as a target in UC as it is commonly genomically altered (activating mutations or fusions), and may be enriched in UC subtypes that are relatively resistant to immune checkpoint blockade. Erdafitinib, a potent and selective inhibitor of FGFRs, represents the first targeted therapy approved for the treatment of UC by virtue of a confirmed response rate of 40% in an open-label, single-armed phase II trial in molecularly selected tumors. The authors provide their expert opinion of its approval and place it in the context of the current and forthcoming treatment strategies for metastatic UC | ||
| 520 | |a EXPERT OPINION: The approval of erdafitinib provides clinicians with an important new treatment option for patients with metastatic UC and projects forward into an era of enhanced molecular precision in identifying effective therapies in UC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Urothelial carcinoma | |
| 650 | 4 | |a bladder cancer | |
| 650 | 4 | |a fibroblast growth factor receptor | |
| 650 | 4 | |a targeted therapy | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Receptors, Fibroblast Growth Factor |2 NLM | |
| 650 | 7 | |a erdafitinib |2 NLM | |
| 650 | 7 | |a 890E37NHMV |2 NLM | |
| 700 | 1 | |a Villamar, Dario M |e verfasserin |4 aut | |
| 700 | 1 | |a Lebenthal, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Vlachostergios, Panagiotis J |e verfasserin |4 aut | |
| 700 | 1 | |a Tagawa, Scott T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 21(2020), 8 vom: 16. Juni, Seite 863-870 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:8 |g day:16 |g month:06 |g pages:863-870 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14656566.2020.1736036 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 8 |b 16 |c 06 |h 863-870 | ||